Abstract The Cancer Programme of the 100,000 Genomes Project was an initiative to
provide whole-genome sequencing (WGS) for patients with cancer, evaluating opportunities …

Importance Real-world data sets that combine clinical and genomic data may be subject to
left truncation (when potential study participants are not included because they have already …

PURPOSE Therapeutically actionable molecular alterations are widely distributed across
cancer types. The National Cancer Institute Molecular Analysis for Therapy Choice (NCI …

The last decade has seen rapid progress in the use of genomic tests, including gene panels,
whole‐exome sequencing, and whole‐genome sequencing, in research and clinical cancer …

With the increasing availability of genomics, routine analysis of advanced cancers is now
feasible. Treatment selection is frequently guided by the molecular characteristics of a …

Over the past decade, multiple trials, including the precision medicine trial National Cancer
Institute-Molecular Analysis for Therapy Choice (NCI-MATCH, EAY131, NCT02465060) …

The scale of tumor genomic profiling is rapidly outpacing human cognitive capacity to make
clinical decisions without the aid of tools. New frameworks are needed to help researchers …

Importance Use of next-generation sequencing (NGS) to identify clinically actionable
genomic targets has been incorporated into routine clinical practice in the management of …

The National Cancer Institute–Molecular Analysis for Therapy Choice (NCI-MATCH) trial is a
national signal-finding precision medicine study that relies on genomic assays to screen and …

Systematic studies evaluating clinical benefit of tumor genomic profiling are lacking. We
conducted a prospective study in 250 patients with select solid tumors at the Cleveland …